Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.47 Analyst target: $14.40 Upside: 483.00%
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.